M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.
Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter ...
Using ribosome engineering (RE), researchers from Shinshu University introduced mutations affecting the protein synthesis ...
Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made ...
Ad hoc announcement pursuant to Art. 53 LR Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent EP4615820 – “Crystalline Forms of Evenamide” is ...
Ad hoc announcement pursuant to Art. 53 LR EP4615820 "Crystalline Forms of Evenamide" is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron's ...
This is where things get really exciting. Nanomaterials are like tiny delivery trucks and super-powered microscopes for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback